



MGFA Scientific Session
2025 AANEM Annual Meeting
Wednesday, October 29, 2025
San Francisco, CA

Myasthenia Gravis Foundation of America invites clinical and scientific experts to share current and prospective peer-reviewed research focused on myasthenia gravis and related disorders of the neuromuscular junction. The MGFA Scientific Session includes presentations highlighting the latest advancements in our understanding of MG etiology, pathogenesis, therapeutic developments, and management.

- Danielle M. Kerkovich, PhD
Vice President, Global Research, MGFA
- **Steering Committee:**
Tuan Vu, MD; Gianvito Masi, MD; Neelam Goyal, MD; Colleen Noviello, PhD;
Ali Habib, MD; Kelly Gwathmey, MD; Richard Nowak, MD, MS

SESSION A – 8:00 – 9:35 a.m.

Welcome and Keynote

8:00 – 8:05 a.m.: *Welcome* – Samantha Masterson, President and CEO, MGFA

8:06 – 8:11 a.m.: *Introduction of Keynote* – Richard Nowak, MD, MS

8:12 – 8:52 a.m.: *Keynote Address: Autoimmune mechanisms elucidated through muscle acetylcholine receptor structures* – Ryan Hibbs, PhD

8:53 – 8:59 a.m.: Q&A - Moderator Ali Habib, MD

Biomarkers and Basic Science

9:00 – 9:08 a.m.: Disease Specific Protein Biomarkers in Acetylcholine Receptor Antibody Seropositive Myasthenia Gravis – Anna Punga MD, PhD

9:09 – 9:17 a.m.: Presentation of Shed Acetylcholine Receptors from Damaged Muscles Triggers Myasthenia Gravis in Rats – Jie Luo, PhD

9:18 – 9:26 a.m.: S-1117, an Engineered Pan-IgG Cleaving Enzyme, Reduces IgG BCR Mediated B Cell Activation and Eliminates Intact Anti-AChR IgG Tissue Deposition in an MG Mouse Model – Liliana Sanmarco, PhD

9:27 – 9:35 a.m.: Q&A - Moderator Ali Habib, MD

9:35 – 10:00 a.m.: Coffee Break

SESSION B – 10:00 a.m. to 11:45 a.m.

Therapeutics and Clinical Trials

10:00 – 10:09 a.m.: Phase III Myasthenia Gravis Inebilizumab Trial (MINT): Efficacy Data in AChR+ Generalized MG Subpopulation Through Week 52 – Richard Nowak, MD, MS

10:10 – 10:19 a.m.: Long-term Safety and Efficacy of Nipocalimab in Generalized Myasthenia Gravis: Vivacity-MG3 Open-label Extension Phase Results – Tuan Vu, MD

10:20 – 10:29 a.m.: Results from the ADAPT JR Study Investigating Intravenous Efgartigimod in Juvenile Generalized Myasthenia Gravis – Abigail Schwaede, MD

10:30 – 10:39 a.m.: Safety and Efficacy Results of Nipocalimab in Adolescents with Generalized Myasthenia Gravis During Active-Treatment and Long-Term Extension phases: Vibrance-MG Phase II/III Study – Jonathan Strober, MD

10:40 – 10:49 a.m.: Phase III Trial Investigating Impact of Intravenous Efgartigimod in Anti-Acetylcholine Receptor Antibody-Negative Generalized Myasthenia Gravis – James F. Howard Jr., MD

10:50 – 10:59 a.m.: Efficacy and Safety of Telitacicept in Patients with Generalized Myasthenia Gravis: Results from a Phase III Study – George Li, MD

11:00 – 11:09 a.m.: Update on the Phase II Part of KYSA-6, an Open-Label, Single-Arm, Multicenter Study of KYV-101, a Fully Human CD19 Chimeric Antigen Receptor T-Cell Therapy in Generalized Myasthenia Gravis – Srikanth Muppidi, MD

11:10 – 11:19 a.m.: Efficacy and Safety of Autologous BCMA-Directed mRNA CAR T-Cell Therapy in Generalized Myasthenia Gravis: 12-Month Follow-Up of a Phase 2B Randomized Placebo-Controlled Trial – Tuan Vu, MD

11:20 – 11:29 a.m.: Top Line Results for MAGIC, a Phase II Trial of DNTH103, an Active C1S Inhibitor, in Generalized Myasthenia Gravis – Pushpa Narayanaswami, MD

11:30 – 11:39 a.m.: Efficacy and Safety of Subcutaneous Self-Administered Gefurulimab in Generalized Myasthenia Gravis (PREVAIL): Topline Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study - Kelly Gwathmey, MD

11:40 - 11:45 a.m.: Q&A – Moderator Neelam Goyal, MD

11:46 a.m. – 1:00 p.m.: Lunch

(Not served at MGFA Scientific Session - On Your Own)

SESSION C – 1:00 pm to 2:30 pm

Patient Care, Hot Topics, Retrospective/Post-Hoc Studies

Theme: Corticosteroids

1:00 – 1:07 p.m.: Longitudinal Associations of Corticosteroid Dose with Corticosteroid Toxicity in Patients with Myasthenia Gravis in the USA – Thomas Ragole, MD

1:08 – 1:15 p.m.: Corticosteroid Dose Tapering during Treatment with Rozanolixizumab in Patients with Generalized Myasthenia Gravis: Post Hoc Analysis – Robert Pascuzzi, MD

1:16 – 1:23 p.m.: Reduction in Oral Glucocorticoid Use at 18 Months Following Efgartigimod Initiation Based on a United States Claims Database – Neelam Goyal, MD

1:24 - 1:31 p.m.: Q&A – Moderator Tuan Vu, MD

Theme: Meningococcal Infection/Immunization

1:32 – 1:39 p.m.: Characterization of Antibiotic Prophylaxis Risk Mitigation Practices Across Eculizumab and Ravulizumab Adult, Phase III Clinical Trials for PNH, AHUS, GMG and NMOSD – Lokesh Jha, MD

1:40 – 1:47 p.m.: Incidence and Outcome of Meningococcal Infection with Eculizumab or Ravulizumab in Patients with Generalized Myasthenia Gravis or Neuromyelitis Optica Spectrum Disorder: An Updated Analysis – Shirali Pandya, PhD

1:48 – 1:55 pm: Q&A – Moderator Richard Nowak, MD, MS

Theme: Diagnosis, Diagnostics, and Management Considerations

1:56 - 2:03 p.m.: Impact of Botulinum Toxin on the Electrodiagnosis of Ocular Myasthenia Gravis: A Case Series – Juan Camilo Ibarra-Jurado, MD

2:04 - 2:11 p.m.: Diaphragmatic Compound Muscle Action Potentials Correlate with the Clinical Severity of Myasthenia Gravis – Hirotomo Suehiro, MD, PhD

2:12 - 2:19 p.m.: The Evolving Treatment Landscape in Myasthenia Gravis: The Value of Shared Decision Making – James F. Howard Jr., MD

2:20 - 2:27 p.m.: Q&A – Moderator Ali Habib, MD

2:28 – 2:30 p.m.: *Final Remarks and Wrap Up* – Danielle M. Kerkovich, PhD, VP for Global Research, MGFA

2:30 – 3:30 p.m.: MGFA Scientific Session Poster Session (Plaza A/B)